Home › Graves Disease
Graves Disease clinical trials recruiting in the U.S.
15 studies for Graves Disease are recruiting participants at sites across the United States.
Cities with the most studies
- Dallas, TX7 studies
- Miami, FL7 studies
- San Antonio, TX6 studies
- Houston, TX6 studies
- Torrance, CA3 studies
- Las Vegas, NV3 studies
- Asheville, NC3 studies
- San Francisco, CA3 studies
- Akron, OH3 studies
- Farmington Hills, MI3 studies
- Memphis, TN3 studies
- Doral, FL3 studies
- Raleigh, NC3 studies
- Havelock, NC3 studies
- McKinney, TX3 studies
- Kansas City, MO3 studies
- El Paso, TX3 studies
- Tucson, AZ3 studies
- Hialeah, FL3 studies
By state
- Arizona5 studies
- California9 studies
- Florida8 studies
- Georgia5 studies
- Kansas4 studies
- Kentucky3 studies
- Maryland3 studies
- Michigan4 studies
- Missouri3 studies
- Nevada4 studies
- New York5 studies
- North Carolina8 studies
- Ohio4 studies
- Pennsylvania3 studies
- Tennessee4 studies
- Texas8 studies
Recently updated studies
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07570316Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 17, 2026 · NCT07661056Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07682896A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07722546A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 25, 2026 · NCT06727604A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 25, 2026 · NCT07018323NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Aug 24, 2026 · NCT07305818Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07753603Preoperative Corticosteroids in Autoimmune Thyroid Disease
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05435547Study of BHV-1300 in Graves' Disease
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jul 31, 2026 · NCT06980649Telehealth Music Therapy for Adults With Endocrine Disorder and Depression
Recruiting
Ages 18 to 65 · All sexes · Updated Jul 30, 2026 · NCT07413874Evaluating an AI Tool for Detecting Thyrotoxic States
RecruitingObservational study
Ages 22 and older · All sexes · Updated Jun 1, 2026 · NCT07017907Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
RecruitingPhase 2
Ages 9 to 17 · All sexes · Updated Jan 27, 2026 · NCT07369063Personalized Treatment in Thyroid Disorders
Recruiting
Ages 21 to 65 · All sexes · Updated Oct 15, 2025 · NCT03517579The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Feb 23, 2024 · NCT06275373From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.